Comprehensive Platform for Target Identification and Validation
WuXi Biology’s integrated Advanced Gene Manipulation (AGM™) platform offers innovative technologies and know-how with comprehensive options from cellular, tissue, and in vivo studies.
CRISPR/Cas9 technology
- Stable or inducible cell line generation (KO,KI, OEX, KD)
- sgRNA library screen (sgRNAi, sgRNAa)
- Allele-specific genome editing
- Genetically engineered mouse models (GEMMs)
- Primary cells, iPSC gene manipulation
- Base-editing
CRISPR screening platform
- In-house pipeline for customized design
- Cancer cell line based positive selection or negative selection screen to identify mechanism of drug resistance or essential genes
- CRISPR screen in cancer cell and T cell co-culture to identify regulators of cancer cell response to T cell cytotoxicity
- Bioinformatics workflow for screening data
- In vivo CRISPR screen for cancer immunotherapy modulators in syngeneic tumor models
AAV Platform
- Customized recombinant AAV (rAAV) genome construction and validation
- General AAV packaging, purification and titering
- Premade AAV control vectors
- Large collection of AAV vectors
- Delivery routes for AAV serotypes
shRNA
• Inducible KD and OEX